NIAID FACT SHEET: Toxoplasmosis

National Institute of Allergy and Infectious Diseases, National Institutes of Health - April 1994


Toxoplasmosis is an infection that is caused by the parasite Toxoplasma gondii. The parasite is carried by cats, birds, and other animals and is found in soil contaminated by cat feces and in meat, particularly pork. The parasite can infect the lungs, retina of the eye, heart, pancreas, liver, colon, and testes. Once T. gondii invades the body, it remains there, but the immune system in a healthy person prevents the parasite from causing disease. If the immune system becomes severely damaged, as in people with AIDS, or is suppressed by drugs, T. gondii can begin to multiply and cause severe disease. The most common site of infection is the brain. When T. gondii invades the brain, causing inflammation, it is called toxoplasmic encephalitis.

Symptoms and Diagnosis

A severe headache that does not respond to pain relievers is often one of the first symptoms of toxoplasmic encephalitis. Toxoplasma infection can also cause weakness on one side of the body, fever, seizures, visual field loss, and difficulty with speaking and walking; later symptoms include confusion, decreased attentiveness, and personality changes. Nausea, dizziness, and vomiting also may result from brain involvement.

Toxoplasma infection is difficult to diagnose, particularly since not all patients show signs or symptoms of infection. Often, a positive response to therapy is used to confirm the diagnosis. Brain scans such as computerized tomography (CT) or magnetic resonance imaging (MRI), are sometimes used to identify brain abnormalities and see if the treatment is working.

Treatment

Acute. There are two drug regimens commonly used for the treatment of acute toxoplasmic encephalitis in people with AIDS. The standard therapy is a combination of pyrimethamine and sulfadiazine; a major drawback of this regimen is the frequency of side effects--more than 40 percent in people with AIDS. An alternative regimen that recently has been found to be effective combines oral clindamycin and pyrimethamine. Folinic acid is administered with both therapies to help prevent some of the side effects.

Maintenance. After treatment is completed, patients must receive maintenance therapy for life to prevent a recurrence. Drugs used in treatment, such as pyrimethamine plus sulfadiazine, are used at a reduced dosage. Some research indicates that clindamycin in combination with pyrimethamine may be effective for maintenance therapy in those unable to tolerate sulfadiazine.

Prevention

Many physicians recommend treatment to prevent the onset of toxoplasmosis in individuals with a positive blood test for T. gondii and a T-cell count under 100. Drugs that are being investigated for their effectiveness in preventing toxoplasmosis include trimethoprim/sulfamethoxazole, pyrimethamine and dapsone in various combinations.

People with HIV who do not show any evidence of having been exposed to T. gondii can take preventive measures to decrease their risk of infection:

* Wear gloves while gardening or working with soil or sand. * Avoid eating raw or undercooked meat and wash hands after handling raw meat or vegetables. * Wear gloves and a mask when cleaning cat litterboxes, or preferably, have someone else change the cat's litter. Litterboxes should be cleaned frequently.

Research

Intensive research efforts are under way to evaluate the effectiveness of different drug regimens, both for treatment of acute infection and for prophylaxis of toxoplasmic encephalitis. Drugs under study include atovaquone with pyrimethamine or sufadiazine.

For information about clincal studies, call the AIDS Clinical Trials Information Service:

1-800-TRIALS-A (1-800-874-2572)

NIAID, a component of the National Institutes of Health, supports research on AIDS and other infectious diseases as well as allergies and immunology. NIH is an agency of the U.S. Public Health Service, U.S. Department of Health and Human Services.

Prepared by:

Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892

Public Health Service U.S. Department of Health and Human Services


DT 9404
DOCN NA940023


Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.
This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1994. AEGIS.